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cantly increased during last five years. There is a need for prevention, treatment
and disease management programs to lower the medical and socioeconomic bur-
den of this disease.
Urinary/Kidney Disorders – Research on Methods
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A SIMULATION MODEL OF THE EFFECTS OF TREATMENTS FOR SECONDARY
HYPERPARATHYROIDISM ON MORTALITY
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) is a common condition in
dialysis, characterized by high levels of associated laboratory parameters (LABS):
parathyroid hormone (PTH), serum calcium (Ca) and phosphorous (P). Cinacalcet
can be effective in controlling LABS in SHPT. Objective of this study was to develop
a model to simulate the impact of cinacalcet versus standard treatment (ST) on
patient mortality.METHODS: The model used the latest data on cinacalcet efficacy
in lowering LABS from the OPTIMA and ADVANCE interventional trials together
with the estimated relationship between LABS and mortality from the ARO obser-
vational study on 7970 haemodialysis patients treated in European Fresenius Med-
ical Care facilities. Patient-level data from the 6-month OPTIMA and 12-month
ADVANCE studies were pooled and regression models were fitted with post-treat-
ment values as the response to derive functions predicting 12-month LABS values
from their starting values, patient characteristics and treatment. After 12 months
LABS were assumed constant except for PTH in ST (assumption of a 170 pg/ml per
year increase). Mortality was calculated as that of the dialysis population multi-
plied by relative risks as function of LABS. The model was compared with a Block
observational study analyzing mortality rates (26-month follow-up) in 19,186 hae-
modialysis patients treated at the DaVita dialysis provider in the US. The simula-
tion was run with patient characteristics replicating the DaVita cohort and base
mortality rates from the US Renal Data System. RESULTS: The simulated death
rates (year 1: cinacalcet 18.4%, ST 22.6%, RR0.81; year 2: cinacalcet 32.9%, ST
40.8%, RR0.81) were close to the observed data in the Block study (year 1: cinacal-
cet 15%, ST 20%, RR0.75; year 2: cinacalcet 30%, ST 37%, RR0.81). CONCLUSIONS:
The model showed effects of cinacalcet on mortality similar to those observed in
the DaVita US cohort. This mortality model will be a useful tool for future health-
economic analyses of cinacalcet in SHPT.
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OBJECTIVES: To explore the known-group validity of the Spanish version of the
self-administered OABq-SF questionnaire, which feasibility, reliability and con-
struct and criterion validities have previously been shown. METHODS: The cultur-
ally adapted Spanish version of OABq-SF was administered on two occasions 3
months apart to a set of patients of both genders, 18 years, diagnosed of OAB
according with standard criteria and a score  8 in OAB-V8 scale and able to un-
derstand and filling-in PRO instruments written in Spanish. Patients were recruited
consecutively at clinics of Urology all over the country. Known-groups validity was
explored using the sample of patients classified in quartiles according to their
responses in the OAB-V8 scale at the baseline visit. Patients were compared in the
OABq-SF: symptom bother and HRQoL. For known-group testing purposes, base-
line scores in the OABq-SF questionnaire were used. ANOVA, descriptive statistics
and Pearson=s r coefficients were computed for data analysis. RESULTS: The study
enrolled a total of 246 OAB patients (mean age 57.7 years; 76% women, 99% Cauca-
sian, 37% active workers and 36% primary schooling) at 18 urological. OAB-V8
scores significantly correlated (Pearson=s r coefficient) with OABq-SF domains;
0.790 and0.659 for symptom bother and HRQoL domains, respectively (p0.001
in both cases). Mean (95% CI) of the OABq-SF domain scores were significantly
different between OAB-V8 quartile groups; 39.1 (36.0-42.3), 48.0 (44.5-51.5), 56.7
(53.6-59.8) and 74.6 (71.4-77.7) points for 1st, 2nd, 3rd and 4th quartile groups,
respectively (F10.5, p0.001) in symptom bother domain, and 66.8 (6.1-70.5), 60.5
(56.4-64.6), 53.5 (49.9-57.2) and 37.8 (34.0-41.6) points average score, respectively
(F32.9, p0.001) in HRQoL domain. CONCLUSIONS: The Spanish version of the
OABq-SF instrument provided evidence of known-group validity according with
patient-rated severity of symptom bother in the OAB-V8 scale.
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IMPROVING PATIENT SAFETY IN THE UK AND ENGAGING PATIENTS IN
RESEARCH: A NEW MODEL FOR THE NHS?
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OBJECTIVES:The purpose of this study was to determine awareness of and interest
in research amongst members of a web-based medicines monitoring service and to
solicit opinions on whether this service should be offered by the NHS. METHODS:
In May 2011, we surveyed 150 uk.MediGuard.org members: 50 in England, Scotland,
and Wales. uk.MediGuard.org is a free medicines monitoring service covering over
2.5 million patients, including 100,000 in the UK. RESULTS: Ninety-one percent of
respondents rate the MediGuard service as good or excellent and 99% are unaware
of similar services in the UK. When asked whether the National Health Service
(NHS) should introduce MediGuard to all patients, 93% responded yes and 89% said
that offering the service would positively impact their impression of the NHS (43%
significantly, 46% somewhat positive impact). While only 12% have ever enrolled in
a trial, 71% were at least somewhat interested in participating in the next 12
months (23% extremely, 17% very, 31% somewhat interested). The primary reason
why patients have not enrolled in a trial is lack of awareness (68%); only 16%
mentioned lack of participation due to concerns about an experimental drug.
CONCLUSIONS: Survey results show that engagement in a medicines monitoring
service is an effective method for improving outcomes and increasing awareness of
clinical trials; pilot studies are now underway. Historically, the NHS has been slow
to pursue public-private partnerships, however, NHS efforts to stimulate on-line
patient engagement have not been a huge success (e.g., HealthSpace enrolled 3,000
in the first year at a cost of £8 million). Recognizing that all UK countries have
initiatives to increase participation in research, perhaps it is time for the NHS to
reconsider the role of partnerships to leverage the explosion of web-based appli-
cations as a method for stimulating research.
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OBJECTIVES: This study aimed to assess the opinion of the French population on
the publication of a list of 77 medicines under regulatory monitoring (surveillance
list, published following market withdrawal of diet adjuvant benfluorex) in France
and more specifically evaluate its impact on consumer behaviour. METHODS: A
total of 928 French individuals answered a phone questionnaire consisting of 37
closed questions and 3 open-ended questions. Respondents were aged 30 and over
since this age group is expected to be more prone to diseases and chronic pathol-
ogies. The study, carried out in March 2011, was compliant with the French Na-
tional INSEE quota methodology. RESULTS: Around 7% of the sample population
declared using at least one of the products included in the French surveillance list.
Of these, over one in three persons indicated their intention to stop or suspend
their treatment in reaction to their medicine’s regulatory surveillance while one in
three persons did not intend to change their treatment intake. Meanwhile, in the
larger study sample, nearly one in six persons declared considering reducing their
medicine purchasing patterns as a result of the surveillance list publication, a
figure in line with studies conducted prior to the publication of the list. Finally,
treatment compliance was reported at 85.8% pre-surveillance list publication and
83.5% post-surveillance list publication. CONCLUSIONS: French consumer confi-
dence in pharmaceuticals in general is mostly unaffected by the new surveillance
list. However, consumer behaviour is strongly affected by product inclusion onto
the surveillance list, especially for those patients treated with at least one listed
treatment. Furthermore, consumer confidence in healthcare regulators, off-label
prescribing and pharmaceutical companies was negatively affected by the benfluo-
rex case. Prescribers will have a pivotal role in maintaining overall confidence
through patient communication and information.
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OBJECTIVES:We use discrete choice experiment to analyze which attributes (qual-
ity, access, and price) influence patients’ choice between health care providers. We
also estimate the willingness-to-pay of respondents for the improvement of health
care characteristics. METHODS: Data was collected via household survey con-
ducted by face-to-face interviews in Hungary, 2010. Respondents were selected
based on multistage random probability method. In total, 1037 respondents filled in
the questionnaire. In DCE, eight choice set for the physician and eight for hospital
services were presented to the respondents in the form of alternative and basic
profiles that contained combinations of attributes of health care services. Attri-
butes and attribute levels were developed on the basis of literature review. For the
analysis binary probit regression with random effects was used including attribute
differences as well as interactions of attribute differences and socio-economic
characteristic as independent variables. Marginal rates of substitution (MRS) were
calculated to indicate the willingness-to-pay of the respondent for the improve-
ments in the attribute levels. RESULTS: The response rate of the survey was 67%.
Significant negative regression coefficients (p0.1) of the interactions between
price and social economic characteristics show that respondents from a village or
the capital, with low education and bad health status were more sensitive to
changes in the price attribute when choosing between health care providers. MRSs
show that respondents are willing to pay the most for the good skills and reputa-
tion of the physician and the attitude of the personnel, followed by modern equip-
ments and maintenance of the office/hospital. Access attributes (travelling and
waiting time in front of the office) were less important. CONCLUSIONS: DCE
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